A systematic review of the budget impact analyses for antitumor drugs of lung cancer

BACKGROUND: Budget impact analyses (BIAs) are used for reimbursement decisions and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs). OBJECTIVES: We systematically reviewed BIAs for antitumor drugs of lung cancer to provide reference for high-value drug budget impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lu, Zhang, Xin, Fu, Wen-Qi, Sun, Cheng-Yao, Zhao, Xian-Ming, Zhou, Liang-Ru, Liu, Guo-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706257/
https://www.ncbi.nlm.nih.gov/pubmed/33292288
http://dx.doi.org/10.1186/s12962-020-00253-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706257/
https://www.ncbi.nlm.nih.gov/pubmed/33292288
http://dx.doi.org/10.1186/s12962-020-00253-5

Ejemplares similares